Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines

References

• Coucke D, Schotsaert M, Libert C, Pringels E, Vervaet C, Foreman P, Saelens X, Remon JP. Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. Vaccine 2009; 27:1279-86; PMID:19114075; https://doi.org/10.1016/j.vaccine.2008.12.013
   PubMed Web of Science ®Google Scholar
• Saito S, Ainai A, Suzuki T, Harada N, Ami Y, Yuki Y, Takeyama H, Kiyono H, Tsukada H, Hasegawa H. The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine. Vaccine 2016; 34:3258-62; https://doi.org/10.1016/j.vaccine.2016.01.020
   Web of Science ®Google Scholar
• Tlaxca JL, Ellis S, Remmele RL Jr. Live attenuated and inactivated viral vaccine formulation and nasal delivery: Potential and challenges. Adv Drug Deliv Rev 2014; 93:56-78; PMID:25312673; https://doi.org/10.1016/j.addr.2014.10.002
   PubMed Web of Science ®Google Scholar
• World Health Organization. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: WHO Press; 2011.
   Google Scholar
• Yuki Y, Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol 2003; 13:293-310; PMID:12931340; https://doi.org/10.1002/rmv.398
   PubMed Web of Science ®Google Scholar
• Sui Z, Chen Q, Fang F, Zheng M, Chen Z. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 2010; 28:7690-8; PMID:20870054; https://doi.org/10.1016/j.vaccine.2010.09.019
   PubMed Web of Science ®Google Scholar
• Wang D, Christopher ME, Nagata LP, Zabielski MA, Li H, Wong JP, Samuel J. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. J Clin Virol 2004; 31(Suppl 1):S99-106; PMID:15567101; https://doi.org/10.1016/j.jcv.2004.09.013
   PubMed Web of Science ®Google Scholar
• Ichihashi T, Yoshida R, Sugimoto C, Takada A, Kajino K. Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model. PLoS One 2011; 6:e24626; PMID:21949735; https://doi.org/10.1371/journal.pone.0024626
   PubMed Web of Science ®Google Scholar
• Ninomiya A, Ogasawara K, Kajino K, Takada A, Kida H. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine 2002; 20:3123-9; PMID:12163263; https://doi.org/10.1016/S0264-410X(02)00261-X
   PubMed Web of Science ®Google Scholar
• Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm 2015; 94:251-63; PMID:26047796; https://doi.org/10.1016/j.ejpb.2015.05.023
   PubMed Web of Science ®Google Scholar
• Rose MA, Zielen S, Baumann U. Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines 2012; 11:595-607; PMID:22827245; https://doi.org/10.1586/erv.12.31
   PubMed Web of Science ®Google Scholar
• Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008; 26:1243-52; PMID:18243429; https://doi.org/10.1016/j.vaccine.2007.12.027
   PubMed Web of Science ®Google Scholar
• Khan T, Heffron CL, High KP, Roberts PC. Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines. Virol J 2014; 11:78; PMID:24884849; https://doi.org/10.1186/1743-422X-11-78
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Ainai A, Ami Y, Nagata N, Iwata N, Kawaguchi A, Suzaki Y, Odagiri T, Tashiro M, Takahashi H, et al. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J Med Virol 2010; 82:1754-61; PMID:20827774; https://doi.org/10.1002/jmv.21824
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura SI, Takahashi H, Sawa H, Chiba J, Kurata T, et al. Synthetic double-stranded RNA Poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 2005; 79:2910-9; PMID:15709010; https://doi.org/10.1128/JVI.79.5.2910-2919.2005
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H. Poly I: polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine 2009; 27:6276-9; PMID:19840660; https://doi.org/10.1016/j.vaccine.2009.04.074
   PubMed Web of Science ®Google Scholar
• Mann AJ, Noulin N, Catchpole A, Stittelaar KJ, de Waal L, Veldhuis Kroeze EJ, Hinchcliffe M, Smith A, Montomoli E, Piccirella S, et al. Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge. PLoS One 2014; 9:e93761; PMID:24850536; https://doi.org/10.1371/journal.pone.0093761
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, Wittes J, Bryant M. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2) and B viruses. Vaccine 1999; 18:899-906; PMID:10580204; https://doi.org/10.1016/S0264-410X(99)00334-5
   PubMed Web of Science ®Google Scholar
• Christensen D, Foged C, Rosenkrands I, Lundberg CV, Andersen P, Agger EM, Nielsen HM. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro, and in vivo, investigations. Int J Pharm 2010; 390:19-24; PMID:19879346; https://doi.org/10.1016/j.ijpharm.2009.10.043
   PubMed Web of Science ®Google Scholar
• Matsui M, Kohyama S, Suda T, Yokoyama S, Mori M, Kobayashi A, Taneichi M, Uchida T. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice. Biochem Biophys Res Commun 2010; 391:1494-9;PMID:20060099;https://doi.org/10.1016/j.bbrc.2009.12.100
   PubMed Web of Science ®Google Scholar
• Thueng-in K, Maneewatch S, Srimanote P, Songserm T, Tapchaisri P, Sookrung N, Tongtawe P, Channarong S, Chaicumpa W. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines. Vaccine 2010; 28:6765-77; PMID:20688037; https://doi.org/10.1016/j.vaccine.2010.07.065
   PubMed Web of Science ®Google Scholar
• Even-Or O, Joseph A, Itskovitz-Cooper N, Samira S, Rochlin E, Eliyahu H, Goldwaser I, Balasingam S, Mann AJ, Lambkin-Williams R, et al. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity. Vaccine 2011; 29:2474-86.
   PubMed Web of Science ®Google Scholar
• Vila A1, Sánchez A, Janes K, Behrens I, Kissel T, Vila Jato JL, Alonso MJ. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 2004; 57:123-31; PMID:14729088; https://doi.org/10.1016/j.ejpb.2003.09.006
   PubMed Web of Science ®Google Scholar
• Singh M, Briones M, O'Hagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release 2001; 70:267-76; PMID:11182197; https://doi.org/10.1016/S0168-3659(00)00330-8
   PubMed Web of Science ®Google Scholar
• Smith LR, Wodal W, Crowe BA, Kerschbaum A, Bruehl P, Schwendinger MG, Savidis-Dacho H, Sullivan SM, Shlapobersky M, Hartikka J, et al. Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines[J]. Hum Vaccin Immunother 2013; 9(6):1333-45; https://doi.org/10.4161/hv.24209
   PubMed Web of Science ®Google Scholar
• Smith A, Perelman M, Hinchcliffe M. Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines. Hum Vaccin Immunother 2014; 10:797-807; PMID:24346613; https://doi.org/10.4161/hv.27449
   PubMed Web of Science ®Google Scholar
• Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001; 51:81-96; PMID:11516781; https://doi.org/10.1016/S0169-409X(01)00171-5
   PubMed Web of Science ®Google Scholar
• Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 2007; 25:2085-94; PMID:17258843; https://doi.org/10.1016/j.vaccine.2006.11.034
   PubMed Web of Science ®Google Scholar
• Song Y, Wang X, Zhang H, Tang X, Li M, Yao J, Jin X, Ertl HC, Zhou D. Repeated low-dose influenza virus infection causes severe disease in mice: A model for vaccine evaluation. J Virol 2015; 89:7841-51; PMID:25995265; https://doi.org/10.1128/JVI.00976-15
   PubMed Web of Science ®Google Scholar